Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K7 | O43318 | 3/20 | 0.52 |
| ▸ | IRAK1 | P51617 | 3/20 | 0.52 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.52 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.42 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1924454 | 0.87 | ALDH1A1 (0.53) | MAP3K7IRAK1IRAK4ALDH1A1PRMT6 | |
| SCHEMBL1924434 | 0.80 | ALDH1A1 (0.49) | ALDH1A1POLBSMN1; SMN2HTT | |
| SCHEMBL20985413 | 0.78 | IDO1 (0.48) | MAP3K7IRAK1IRAK4ADORA2A | |
| SCHEMBL1926108 | 0.78 | ALDH1A1 (0.47) | MAP3K7IRAK1IRAK4ALDH1A1HRH3 | |
| SCHEMBL5471566 | 0.75 | DRD4 (0.56) | ALDH1A1POLBHTT | |
| SCHEMBL6229878 | 0.73 | ALDH1A1 (0.71) | ALDH1A1POLBSMN1; SMN2HTT | |
| SCHEMBL29313493 | 0.72 | MAP3K7 (0.77) | MAP3K7IRAK1IRAK4ALDH1A1SMN1; SMN2 | |
| SCHEMBL14315230 | 0.71 | ALDH1A1 (0.51) | ALDH1A1POLBSMN1; SMN2HTT | |
| SCHEMBL5911642 | 0.71 | ALDH1A1 (0.51) | ALDH1A1POLBSMN1; SMN2HTT | |
| SCHEMBL5470925 | 0.71 | TRPC5 (0.56) | TRPC5ALDH1A1HRH3POLBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293923-B2 | Indazole derivatives as modulators of interleukin-1 receptor-associated kinase | BIOGEN IDEC MA INC. (US) | 2012-10-23 | — | — | US | disclosed |
| US-20110152260-A1 | Indazole derivatives as modulators of interleukin-1 receptor-associated kinase | BIOGEN IDEC MA INC. (US) | 2011-06-23 | — | — | US | disclosed |
| EP-1434579-B1 | IMIDAZOLE DERIVATIVES AS ANTIINFLAMMATORY AGENTS | AMGEN INC (US) | 2011-06-08 | — | — | EP | disclosed |
| US-20100048565-A1 | BENZIMIDAZOLE DERIVATIVES | FRENKEL ALEXANDER DAVID | 2010-02-25 | — | — | US | disclosed |
| US-20100048565-A1 | BENZIMIDAZOLE DERIVATIVES | FRENKEL ALEXANDER DAVID | 2010-02-25 | — | — | US | disclosed |
| US-20100048565-A1 | BENZIMIDAZOLE DERIVATIVES | FRENKEL ALEXANDER DAVID | 2010-02-25 | — | — | US | disclosed |
| US-7635774-B2 | 2-Amino-imidazole derivatives; modulate the expression and/or function of proteins involved in inflammation, immune response regulation and cell proliferation | AMGEN INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-7635774-B2 | 2-Amino-imidazole derivatives; modulate the expression and/or function of proteins involved in inflammation, immune response regulation and cell proliferation | AMGEN INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-7635774-B2 | 2-Amino-imidazole derivatives; modulate the expression and/or function of proteins involved in inflammation, immune response regulation and cell proliferation | AMGEN INC. (US) | 2009-12-22 | — | — | US | disclosed |
| EP-2061786-A2 | INDAZOLE DERIVATIVES AS MODULATORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE | Biogen Idec MA Inc. (US) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008030584-A2 | INDAZOLE DERIVATIVES AS MODULATORS OF INTERLEUKIN- 1 RECEPTOR-ASSOCIATED KINASE | BIOGEN IDEC MA INC. (US) | 2008-03-13 | — | — | WO | disclosed |
| US-20070037803-A1 | 2-Amino-imidazole derivatives; modulate the expression and/or function of proteins involved in inflammation, immune response regulation and cell proliferation | AMGEN SF, LLC (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037803-A1 | 2-Amino-imidazole derivatives; modulate the expression and/or function of proteins involved in inflammation, immune response regulation and cell proliferation | AMGEN SF, LLC (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037803-A1 | 2-Amino-imidazole derivatives; modulate the expression and/or function of proteins involved in inflammation, immune response regulation and cell proliferation | AMGEN SF, LLC (US) | 2007-02-15 | — | — | US | disclosed |
| US-7132438-B2 | Benzimidazole derivatives | AMGEN INC. (US) | 2006-11-07 | — | — | US | disclosed |
| EP-1434579-A1 | IMIDAZOLE DERIVATIVES AS ANTIINFLAMMATORY AGENTS | Tularik Inc. (US) | 2004-07-07 | — | — | EP | disclosed |
| US-20030144286-A1 | Benzimidazole derivatives | TULARIK, INC | 2003-07-31 | — | — | US | disclosed |
| WO-2003030902-A1 | IMIDAZOLE DERIVATES AS ANTI-INFLAMMATORY AGENTS | TULARIK INC. (US) | 2003-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037803-A1 | 2-Amino-imidazole derivatives; modulate the expression and/or function of proteins involved in inflammation, immune response regulation and cell proliferation | IDO2, IRF2BP2, IRF3 | MAP3K7 294/4885IRAK1 121/4885IRAK4 102/4885 |
| US-20030144286-A1 | Benzimidazole derivatives | NFATC1, STAT1, IRF3 | MAP3K7 330/4885IRAK1 87/4885IRAK4 55/4885 |
| US-20110152260-A1 | Indazole derivatives as modulators of interleukin-1 receptor-associated kinase | IRAK1, IRAK2, IRAK3 | MAP3K7 55/4885IRAK1 1/4885IRAK4 4/4885 |
| US-20100048565-A1 | BENZIMIDAZOLE DERIVATIVES | NFATC1, STAT1, IRF3 | MAP3K7 330/4885IRAK1 87/4885IRAK4 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.